2022
Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer
Eita A, Mohamed N, Rybkin A, Kang J, Fiasconaro M, Zhigang Z, Zakeri K, Yu Y, Sadaka E, Sherman E, Dunn L, Cracchiolo J, Wong R, Cohen M, Lee N. Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer. The Laryngoscope 2022, 133: 1138-1145. PMID: 35801573, PMCID: PMC10547133, DOI: 10.1002/lary.30279.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellHumansHypopharyngeal NeoplasmsHypopharynxLaryngeal NeoplasmsLarynxNeoplasm StagingOrgan PreservationConceptsUnivariate analysisLocoregional failureT4 laryngealNonoperative managementHypopharyngeal cancerRadiation therapyPercutaneous endoscopic gastrostomy tubeHypopharynx cancer patientsYear OS ratesDisease-free survivalNon-surgical managementHypopharynx groupsInoperable diseaseLast followUnresectable diseaseChemoradiation therapyNodal statusGastrostomy tubeHypopharynx cancerOS ratesStage T4Cancer patientsFunctional outcomeTracheostomy tubeOrgan preservation
2019
Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer
Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, Riaz N, McBride SM, Tsai CJ, Kang J, Yu Y, Chen L, Sherman E, Dunn L, Pfister DG, Tan J, Rupert R, Bonomi M, Zhang Z, Lobaugh SM, Grecula JC, Mitchell DL, Wobb JL, Miller ED, Blakaj DM, Diavolitsis VM, Lee N, Bhatt AD. Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer. International Journal Of Cancer 2019, 147: 107-115. PMID: 31609479, DOI: 10.1002/ijc.32736.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCetuximabChemoradiotherapyCisplatinFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm StagingPapillomaviridaePapillomavirus InfectionsRandomized Controlled Trials as TopicSquamous Cell Carcinoma of Head and NeckSurvival RateConceptsLocoregional failureOverall survivalDistant metastasisReduced hazardMultivariable analysisKaplan-MeierHuman papillomavirus-unrelated headNeck squamous cell carcinomaPlatinum-based regimensSquamous cell carcinomaSuperior locoregional controlCumulative incidence functionDefinitive chemoradiationDefinitive radiotherapyLocoregional controlAdvanced headClinical characteristicsCumulative incidenceConcurrent cetuximabPropensity matchingYear OSCell carcinomaHuman papillomavirusNeck cancerProportional hazards
2018
First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology
Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. European Urology Oncology 2018, 1: 378-385. PMID: 31158076, DOI: 10.1016/j.euo.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedFollow-Up StudiesHumansMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualPostoperative PeriodPrognosisProstatectomyProstate-Specific AntigenProstatic NeoplasmsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSalvage TherapySurvival AnalysisConceptsBone metastasis-free survivalProstate cancer-specific survivalUltrasensitive prostate specific antigenOverall survivalBiochemical relapseProstate-specific antigenRadical prostatectomyMultivariate analysisProstate-specific antigen levelImmediate adjuvant therapyOccult prostate cancerOccult systemic diseaseCancer-specific survivalEarly salvage radiotherapyHigh-risk diseaseKaplan-Meier methodTraditional risk factorsMetastasis-free survivalPrediction of outcomeProstate cancer pathologyAdjuvant therapySalvage radiotherapyHormone therapyIndependent predictorsStudy endpointWhole Versus Partial Bladder Radiation
Kang J, Steinberg M, Kupelian P, Alexander S, King C. Whole Versus Partial Bladder Radiation. American Journal Of Clinical Oncology 2018, 41: 107-114. PMID: 26535994, DOI: 10.1097/coc.0000000000000237.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinoma, Transitional CellCohort StudiesDisease-Free SurvivalFemaleGeriatric AssessmentHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingOrgan Sparing TreatmentsPrognosisRadiation Dose HypofractionationRadiation InjuriesRadiotherapy, Image-GuidedRadiotherapy, Intensity-ModulatedRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesUrinary Bladder NeoplasmsConceptsOverall survivalLymph nodesWhole bladderLocal controlMuscle-invasive bladder cancerMuscle-invasive recurrenceMulti-institutional cohortSimultaneous integrated boostIntensity-modulated radiation therapyDefinitive chemoradiationPrimary endpointSecondary endpointsBladder treatmentLocal recurrenceUrothelial cancerMean ageBladder cancerIntegrated boostInstitutional experienceRetrospective analysisBladder wallBoost volumeRadiation therapySimilar survivalTherapeutic ratio